IPO Timeline
Broker Results (T-2)
2020-04-22
Some brokers release in afternoon
Grey Market (T-1)
2020-04-23
Afternoon
HKEX Allotment (T-1)
2020-04-23
Evening
Registrar Allotment (T-1)
2020-04-23
Evening
Listing Day (T)
2020-04-24
First day of trading
Company Overview
| Stock Name | 康方生物科技(開曼)有限公司 - B |
|---|---|
| Stock Code | 09926 |
| Company Full Name | 康方生物科技(開曼)有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，專注於腫瘤學及免疫學治療領域。 |
| Listing Date | 2020-04-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國廣東省中山市火炬開發區神農路6號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.akesobio.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 16.18 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 49.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 1,290,322,640 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 24.3 |
|---|---|
| First Day Open | HK$ 23.5 |
| First Day Change | 50.19% |
| First Day Volume | 98779200.0 |
| First Day Turnover | 2372500000.0 |
Use of Proceeds
| Use of Proceeds | 1、約75.0%，或1,827.7百萬港元，將主要用于以下產品研發及商業化； 2、約15.0%，或365.5百萬港元，將用于在中國廣州及中山發展生產及研發設施，其中大部分將用于購買新機器、儀器及設備以及擴展生產設施； 3、約10.0%，或243.7百萬港元，將用于我們的一般公司及營運資金用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
摩根士丹利亚洲有限公司 CE AAD291
J.P. Morgan Securities (Far East) Limited CE AAB026
Overall Coordinators (4)
摩根士丹利亚洲有限公司 CE AAD291
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
交银国际证券有限公司 CE APJ121
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (7)
摩根士丹利亚洲有限公司 CE AAD291
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
交银国际证券有限公司 CE APJ121
中国国际金融香港证券有限公司 CE AEN894
中银国际亚洲有限公司 CE AET863
招银国际金融有限公司 CE AJB801
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (7)
摩根士丹利亚洲有限公司 CE AAD291
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
交银国际证券有限公司 CE APJ121
中国国际金融香港证券有限公司 CE AEN894
中银国际亚洲有限公司 CE AET863
招银国际金融有限公司 CE AJB801
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | AIHC Master Fund | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
| 2 | Boyu Capital Opportunities Master Fund | 78,084,680 HKD | — | 3.03% | — | 6 months | 2020-10-24 |
| 3 | CRF Investment Holdings Company Limited | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
| 4 | Fidelity International | 507,615,140 HKD | — | 19.67% | — | 6 months | 2020-10-24 |
| 5 | Hankang Biotech Fund I, L.P. | 23,428,640 HKD | — | 0.91% | — | 6 months | 2020-10-24 |
| 6 | Hudson Bay Master Fund LTD | 78,084,680 HKD | — | 3.03% | — | 6 months | 2020-10-24 |
| 7 | Lake Bleu Prime Healthcare Master Fund Limited | 351,429,600 HKD | — | 13.62% | — | 6 months | 2020-10-24 |
| 8 | OrbiMed Funds | 117,143,200 HKD | — | 4.54% | — | 6 months | 2020-10-24 |
| 9 | 中国国有企业结构调整基金股份有限公司 | 39,042,340 HKD | — | 1.51% | — | 6 months | 2020-10-24 |
Directors & Management
| Chairman | 夏瑜 |
|---|---|
| Company Secretary | 席曉捷;梁慧欣 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 夏瑜及家族成員(12.99%);深圳市創新投資集團有限公司(8.99%);李百勇及家族成員(6.50%);姚毓林(5.94%);鄭遜(5.93%);王忠民及家族成員(5.62%) |
|---|
IPO Timeline
